http://jcps.bjmu.edu.cn

中国药学(英文版) ›› 2020, Vol. 29 ›› Issue (10): 701-710.DOI: 10.5246/jcps.2020.10.065

• 【研究论文】 • 上一篇    下一篇

叶酸靶向聚合物纳米粒共传输紫杉醇和吉西他滨用于乳腺癌的治疗

雷萌1,3*, 王雪源2, 苗航1, 王佳3, 沙思佳1, 朱姜2, 朱永强2*   

  1. 1. 南京林业大学 理学院, 江苏 南京 210037
    2. 南京师范大学 生命科学学院, 江苏 南京 210046
    3. 江苏正大丰海制药有限公司, 江苏 南京 210046
  • 收稿日期:2020-08-23 修回日期:2020-09-01 出版日期:2020-10-31 发布日期:2020-09-20
  • 通讯作者: Tel.: +86-25-85427621; +86-25-85891591, E-mail: hk-lm@163.com; zhyqscu@hotmail.com
  • 基金资助:
    National Natural Science Foundation of China (Grant No. 21877061), Natural Science Foundation of Jiangsu Province (Grant No. BK20171448), National and Local Joint Engineering Research Center of Biomedical Functional Materials.

Co-delivery of paclitaxel and gemcitabine via folic acid-conjugated polymeric multi-drug nanoparticles (FA-PMDNPs) for the treatment of breast cancer

Meng Lei1,3*, Xueyuan Wang2, Hang Miao1, Jia Wang3, Sijia Sha1, Jiang Zhu2, Yongqiang Zhu2*   

  1. 1. College of Science, Nanjing Forestry University, Nanjing 210037, China
    2. College of Life Science, Nanjing Normal University, Nanjing 210046, China
    3. Jiangsu Chia Tai Fenghai Pharmaceutical Co. Ltd., Nanjing 210046, China
  • Received:2020-08-23 Revised:2020-09-01 Online:2020-10-31 Published:2020-09-20
  • Contact: Tel.: +86-25-85427621; +86-25-85891591, E-mail: hk-lm@163.com; zhyqscu@hotmail.com
  • Supported by:
    National Natural Science Foundation of China (Grant No. 21877061), Natural Science Foundation of Jiangsu Province (Grant No. BK20171448), National and Local Joint Engineering Research Center of Biomedical Functional Materials.

摘要:

针对肿瘤细胞不同信号通路的多药递药系统具有协同治疗的作用。本文中, 我们开发了一种由聚-L-赖氨酸(PLL)和负载有紫杉醇/吉西他滨的聚谷氨酸(PGA-PTXPGA-GEM)组装的叶酸(FA)修饰的聚合物多药纳米粒(FA-PMDNPs), 用于FA受体靶向的乳腺癌协同治疗。PGA富含大量的羧基, 为药物负载提供了充足的反应位点和负电荷。透射电子显微(TEM)结果表明制备的FA-PMDNPs粒径均一, 为球形。溶血实验表明FA-PMDNP具有良好的生物相容性。由于乳腺癌细胞(4T1)FA受体(FR)高表达, 体外细胞活性和体内疗效结果表明FA-PMDNP比单药能够更有效地抑制乳腺癌细胞(4T1)的增殖。与单药相比, FA-PMDNPs可以有效地靶向癌细胞。因此, FA受体靶向双重载药递药系统是一种具有潜力的肿瘤纳米治疗平台。

关键词: 叶酸受体靶向, 聚合物纳米粒, 联合化疗, 乳腺癌, 药物靶向递送

Abstract:

Multi-drug delivery focuses on different signaling pathways in cancer cells and has synergistic antiproliferative effects. In this manuscript, we developed folic acid (FA)-conjugated polymeric multi-drug nanoparticles (FA-PMDNPs) consisting of poly-L-lysine (PLL) and poly glutamic-conjugated PTX/GEM (PGA-PTX and PGA-GEM) for FA receptor-targeted synergistic breast cancer therapy. The carboxyl-rich structure of PGA provided plenty reaction sites and negative charge for drug loading. Transmission electron microscopy (TEM) results showed that FA-PMDNPs had uniform particle size and spherical morphology. The hemolysis study proved that FA-PMDNPs had good biocompatibility. In vitro cell viability and in vivo studies showed that FA-PMDNPs more effectively inhibited the proliferation of FA receptor (FR)-overexpressing breast cancer cells (4T1) than the pure drugs.Consequently, these results demonstrated that FA-PMDNPs could be effectively targeted at cancer cells compared with free drugs, indicating their strong potential as efficient multi-drug-carrying nano-platforms for cancer treatment. 

Key words: FA-receptor targeted, Polymeric nanoparticles, Combined chemotherapy, Breast cancer, Drug targeted delivery

中图分类号: 

Supporting:

Supporting Information

1. Synthesis of poly (L-lysine) (PLL)

N6-Cbz-L-Lysine (5.0 g, 17.8 mmol) in THF (65 mL) was reacted with triphosgene (2.1 g, 7.2 mmol) and the reaction was allowed at 50 ºC for 3 h under nitrogen[1]. Lys (Z)-NCA was precipitated with the addition of cold n-hexane in the reaction and the product was filtered and dried at room temperature. 1H NMR (400 MHz, DMSO-d6) δ: 9.11 (1Hα-NH), 7.34 (5H, Ph), 5.00 (2H, CH2Ph), 4.42 (1H, -CH), 2.98 (2H, -CH2), 1.69 (2H, -CH2), 1.4 (2H, -CH2), 1.28 (2H, -CH2). FT-IR (cm-1): 943 (O=C-O-C=O in the NCA), 1688 (C=O in the Cbz group), 1774, 1812 (C=O in the NCA), 1250 (C-O in the Cbz group), 740 cm−1, 697 cm−1 (the deformation vibration of benzene ring).

Lys (Z)-NCA (5.1 g, 16.6 mmol) was dissolved in DMF (25 mL) under nitrogen. Hexylamine (55.6 mg, 0.6 mmol) dissolved in DMF (1 mL) was injected into the Lys (Z)-NCA solution and the reaction was allowed at 35 ºC for 72 h under nitrogen. Then PLL (Z) was precipitated with the addition of ice-cold methyl tert-butyl ether and the product was filtered and dried at room temperature. 1H NMR (400 MHz, DMSO-d6) δ: 7.32 (ArH in the Cbz group), 4.99 (-CH2 in the Cbz group) and 0.82 (-CH3 in hexylamine). FT-IR (cm−1): 1692, 1627, 1537, 1250, 740, 697.

PLL (Z) (3.6 g) was dissolved in HBr (13.2 g, 33 wt% in acetic acid) and the reaction was stirred at room temperature for 2 h. Then, PLL was precipitated with the addition of ice-cold methyl tert-butyl ether in the reaction and the product was filtered and dried at room temperature. 1H NMR (400 MHz, D2O) δ: 4.27 (-CH), 1.13-1.84 (-CH2 in PLL and hexylamine) 0.82 (-CH3 in hexylamine). FT-IR (cm−-1): 1632, 1541.

2. Synthesis of poly (L-glutamic) acid (PGA)

L-Glutamic acid-5-(phenylmethyl) ester (5.0 g, 21.1 mmol) in THF (65 mL) was reacted with triphosgene (2.5 g, 8.4 mmol) and the reaction was allowed at 50 ºC for 3 h under nitrogen[2]. GluB-NCA was precipitated with the addition of ice-cold n-hexane in the reaction and the product was filtered and dried at room temperature. 1H NMR (400 MHz, DMSO-d6) δ: 9.12 (1H, α-NH), 7.48–7.23 (5H, Ph), 5.10 (2H, -CH2Ph), 4.45 (1H, -CH), 2.53 (2H, -CH2), 1.99 (2H, -CH2). FT-IR (cm−1): 927 (O=C-O-C=O in the NCA), 1703 (C=O in the Cbz group), 1780 (C=O in the NCA), 744 cm−1, 696 cm−1 (the deformation vibration of benzene ring).

GluB-NCA (4.5 g, 17.2 mmol) was dissolved in DMF (25 mL) under nitrogen. Hexylamine (31. 6 mg, 0.3 mmol) dissolved in DMF (1 mL) was injected into the GluB-NCA solution and the reaction was allowed at 35 oC for 72 h under nitrogen. Then PBLG was precipitated with the addition of ice-cold methyl tert-butyl ether in the reaction and the product was filtered and dried at room temperature. 1H NMR (400 MHz, DMSO-d6) δ: 7.24 (Ph in the Cbz), 5.03 (-CH2 in the Cbz), 3.93 (-CH), 0.81 (-CH3 in hexylamine). FT-IR (cm1): 3292, 1652, 1550, 740, 690.

PBLG (3.4 g) dissolved in methanol (20 mL) was added to sodium hydroxide solution (3 mL, 10 M). The reaction was allowed at room temperature for 3 h. Then, the reaction solution was filtered and dried at room temperature to get a white solid. The solid was stirred in 5 mL of EA/HCl for 5 min and solvent was removed in vacuo to give the title compound. 1H NMR (400 MHz, D2O) δ: 12.13 (-COOH), 4.24 (-CH), 0.84 (-CH3 in hexylamine). FT-IR (cm1): 3292, 1718, 1635, 1539.

 

 

Scheme S1. Synthesis of the PLL.

 

 

Scheme S2. Synthesis of the PGA.

 

 

Figure S1. Characterization of the compounds. (A) FT-IR spectra of Lys-NCA, PLL(Z) and PLL. (B) 1H NMR spectra of Lys-NCA, PLL(Z) and PLL. (C) FT-IR spectra of BLG-NCA, PBLG and PGA. (D) 1H NMR spectra of BLG-NCA, PBLG and PGA.

 

 

Scheme S3. Synthesis of the FA-OH.

 

 

Scheme S4. Synthesis of PGA-PTX, PGA-GEM and PGA-FA.

 

 

Figure S2. FT-IR spectra and 1H NMR spectra of PGA-PTX, PGA-GEM and PGA-FA.

 

 

Figure S3. Hydration particle size (A), and zeta potential (B) of different mass ratios in FA-PMDNPs.

References

[1] Noh I, Kim H O, Choi J, et al. Co-delivery of paclitaxel and gemcitabine via CD44-targeting nanocarriers as a prodrug with synergistic antitumor activity against human biliary cancer. Biomaterials, 2015; 53: 763-774.

[2] Lee D, Choe K, Jeong Y, et al. Establishment of a controlled insulin delivery system using a glucose-responsive double-layered nanogel. RSC Advances, 2015, 5(19): 14482-14491.